Published in Clin Cancer Res on February 09, 2010
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Treating metastatic cancer with nanotechnology. Nat Rev Cancer (2011) 3.30
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experience. Ann Oncol (2012) 1.35
Survival of 1,181 patients in a phase I clinic: the MD Anderson Clinical Center for targeted therapy experience. Clin Cancer Res (2012) 1.29
Seamless phase I-II trial design for assessing toxicity and efficacy for targeted agents. Clin Cancer Res (2010) 1.12
Outcomes of research biopsies in phase I clinical trials: the MD anderson cancer center experience. Oncologist (2011) 1.02
Dual EGFR inhibition in combination with anti-VEGF treatment: a phase I clinical trial in non-small cell lung cancer. Oncotarget (2013) 0.95
Adaptive designs for identifying optimal biological dose for molecularly targeted agents. Clin Trials (2014) 0.95
Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice. Br J Pharmacol (2012) 0.92
Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. Mol Cancer Ther (2013) 0.91
Clinical development of new drug-radiotherapy combinations. Nat Rev Clin Oncol (2016) 0.91
Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann Oncol (2013) 0.91
American Society of Clinical Oncology policy statement update: the critical role of phase I trials in cancer research and treatment. J Clin Oncol (2014) 0.90
Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities. Front Pharmacol (2015) 0.89
Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin Cancer Res (2014) 0.88
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations. Mol Cancer Ther (2013) 0.87
Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection. Cancer Chemother Pharmacol (2012) 0.87
Melanoma patients in a phase I clinic: molecular aberrations, targeted therapy and outcomes. Ann Oncol (2013) 0.85
Phase I pharmacokinetic and pharmacodynamic evaluation of combined valproic acid/doxorubicin treatment in dogs with spontaneous cancer. Clin Cancer Res (2010) 0.82
The inverted pyramid of biomarker-driven trials. Nat Rev Clin Oncol (2011) 0.82
Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers. Oncotarget (2016) 0.81
Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials. PLoS One (2011) 0.81
Phase I trials of antitumour agents: fundamental concepts. Ecancermedicalscience (2015) 0.80
The changing landscape of phase I trials in oncology. Nat Rev Clin Oncol (2015) 0.79
Early phase clinical trials to identify optimal dosing and safety. Mol Oncol (2014) 0.78
Precision medicine needs randomized clinical trials. Nat Rev Clin Oncol (2017) 0.77
N of 1 case reports of exceptional responders accrued from pancreatic cancer patients enrolled in first-in-man studies from 2002 through 2012. Oncoscience (2015) 0.77
Can knowledge of germline markers of toxicity optimize dosing and efficacy of cancer therapy? Biomark Med (2012) 0.77
Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic. Oncologist (2011) 0.77
Finding the right dose for cancer therapeutics--can we do better? Clin Cancer Res (2010) 0.76
TEAMS: Toxicity- and Efficacy-based Dose Insertion Design with Adaptive Model Selection for Phase I/II Dose-Escalation Trials in Oncology. Stat Biosci (2015) 0.75
Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013. Int J Cancer (2016) 0.75
Lapatinib Plasma and Tumor Concentrations and Effects on HER Receptor Phosphorylation in Tumor. PLoS One (2015) 0.75
Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies. J Biom Biostat (2016) 0.75
Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Reporting results of cancer treatment. Cancer (1981) 28.83
Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med (2005) 8.25
Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol (1995) 5.86
Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA (2004) 4.36
Perceptions of patients and physicians regarding phase I cancer clinical trials: implications for physician-patient communication. J Clin Oncol (2003) 3.31
Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer (1971) 3.04
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Rethinking risk-benefit assessment for phase I cancer trials. J Clin Oncol (2006) 2.73
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst (1993) 2.57
EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA. Cancer Chemother Rep (1964) 2.55
Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med (1981) 2.50
Phase I trial design for solid tumor studies of targeted, non-cytotoxic agents: theory and practice. J Natl Cancer Inst (2004) 2.26
Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol (2000) 2.21
Phase I clinical trial design in cancer drug development. J Clin Oncol (2000) 2.14
Dose selection in phase I studies: why we should always go for the top. J Clin Oncol (2008) 2.08
Therapeutic response in phase I trials of antineoplastic agents. Cancer Treat Rep (1986) 1.91
New paradigm in dose-finding trials: patient-specific dosing and beyond phase I. Clin Cancer Res (2005) 1.70
Response rates, duration of response, and dose response effects in phase I studies of antineoplastics. Invest New Drugs (1991) 1.67
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer (2008) 1.52
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Br J Cancer (2009) 1.44
Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol (1988) 1.43
Responses and toxic deaths in phase I clinical trials. Ann Oncol (1990) 1.43
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience. Cancer (2009) 1.39
Clinical trial design for target-based therapy. Oncologist (2002) 1.36
Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. Cancer Res (1986) 1.12
Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res (2004) 1.12
Risks and benefits associated with novel phase 1 oncology trial designs. Cancer (2007) 1.07
On the nature and ethics of phase I clinical trials of cancer chemotherapies. JAMA (1982) 1.00
Critical role of phase I clinical trials in cancer treatment. American Society of Clinical Oncology. J Clin Oncol (1997) 0.98
Clinical trial design for target specific anticancer agents. Invest New Drugs (2003) 0.98
Survival analysis. Methods Mol Biol (2007) 0.93
The design of clinical trials for new molecularly targeted compounds: progress and new initiatives. Curr Pharm Des (2002) 0.91
Dose selection in phase I studies: why we should always go for the most effective. J Clin Oncol (2008) 0.90
The needs of science vs the needs of patients: ethical concerns in cancer clinical trials. Cleve Clin J Med (2003) 0.89
Ethical issues in the development of new agents. Invest New Drugs (1999) 0.88
Risks and benefits of phase 1 clinical trials evaluating new anticancer agents: a case for more innovation. JAMA (2004) 0.86
Assessing cancer clinical trials: will your patient benefit from a 'breakthrough'? Cleve Clin J Med (2002) 0.81
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys (2002) 6.82
Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet (2012) 6.21
PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol (2012) 4.77
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst (2009) 4.36
Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res (2008) 4.29
PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther (2011) 4.22
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol (2012) 4.19
Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 4.06
Ovarian cancer. Lancet (2009) 3.95
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Retracted The influence of resection and aneuploidy on mortality in oral leukoplakia. N Engl J Med (2004) 3.22
Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol (2011) 3.19
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol (2008) 3.16
Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res (2012) 3.14
Cancer: the road to Amiens. J Clin Oncol (2008) 3.10
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma. J Clin Oncol (2012) 3.08
Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer. Cancer Prev Res (Phila) (2012) 3.03
Risks and benefits of phase 1 oncology trials, revisited. N Engl J Med (2005) 2.98
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol (2012) 2.86
Sweet's syndrome revisited: a review of disease concepts. Int J Dermatol (2003) 2.83
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol (2007) 2.80
Bayesian clinical trials at the University of Texas M. D. Anderson Cancer Center. Clin Trials (2009) 2.79
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Epstein-Barr virus and cancer. Clin Cancer Res (2004) 2.78
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer (2007) 2.62
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst (2006) 2.61
Redesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance. Int J Radiat Oncol Biol Phys (2012) 2.55
Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol (2002) 2.52
Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer (2005) 2.49
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol (2009) 2.48
Change in tumor size by RECIST correlates linearly with overall survival in phase I oncology studies. J Clin Oncol (2012) 2.48
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2005) 2.47
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol (2010) 2.43
Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol (2007) 2.40
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol (2012) 2.31
PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res (2012) 2.27
Targeted therapy in non-small-cell lung cancer--is it becoming a reality? Nat Rev Clin Oncol (2010) 2.26
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol (2007) 2.24
Equipoise lost: ethics, costs, and the regulation of cancer clinical research. J Clin Oncol (2010) 2.16
AnimalTFDB: a comprehensive animal transcription factor database. Nucleic Acids Res (2011) 2.15
Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation. Gynecol Oncol (2009) 2.15
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer. J Clin Oncol (2009) 2.15
Advance care planning in patients with cancer referred to a phase I clinical trials program: the MD Anderson Cancer Center experience. J Clin Oncol (2012) 2.09
Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer (2006) 2.04
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol (2012) 2.04
Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis. Cancer (2004) 2.02
Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila) (2009) 1.99
Recombinant human erythropoietin as an adjunct to radiation therapy and cisplatin for stage IIB-IVA carcinoma of the cervix: a Southwest Oncology Group study. Gynecol Oncol (2004) 1.96
Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol (2010) 1.95
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther (2008) 1.88
Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol (2009) 1.84
Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res (2012) 1.83
PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One (2011) 1.80
Epidermal growth factor receptor expression and gene copy number in the risk of oral cancer. Cancer Prev Res (Phila) (2010) 1.80
Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J Natl Cancer Inst (2007) 1.79
Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-beta expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst (2003) 1.75
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. J Clin Oncol (2009) 1.74
Mortality risk from squamous cell skin cancer. J Clin Oncol (2005) 1.74
A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res (2011) 1.71
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) (2011) 1.70
BRAF(V600) inhibitor GSK2118436 targeted inhibition of mutant BRAF in cancer patients does not impair overall immune competency. Clin Cancer Res (2012) 1.70
Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2008) 1.69
Sarcoidosis and malignancy. Clin Dermatol (2007) 1.67
Objective detection and delineation of oral neoplasia using autofluorescence imaging. Cancer Prev Res (Phila) (2009) 1.66
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol (2006) 1.64
The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol (2011) 1.62
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Noninvasive evaluation of oral lesions using depth-sensitive optical spectroscopy. Cancer (2009) 1.61
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma. J Clin Oncol (2007) 1.61
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. Clin Cancer Res (2009) 1.60